Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by 16c; offers guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $229.85 -0.17%
EPS Growth %: +174.9%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +174.9%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $5.02, $0.16 worse than the analyst estimate of $5.18. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $1.01 billion.
GUIDANCE:
Jazz Pharmaceuticals sees FY2024 EPS of $18.15-$19.35, versus the consensus of $19.62. Jazz Pharmaceuticals sees FY2024 revenue of $4-4.2 billion, versus the consensus of $4.081 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillerKnoll, Inc. (MLKN) Tops Q4 EPS by 4c
- Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
- Currenc Group suspends Indonesian WalletKu unit operations
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
